AC Bioscience secures CHF 1 million in a seed round

Based at the EPFL Innovation Park, AC BioScience is focused on personalized molecular therapies; that is, medical care designed to optimize efficiency or therapeutic benefit for particular groups of patients by using molecular profiling. The start-up with experienced founders identifies and develops only those molecules with a previous history of extensive and successful pre-clinical research. The company does not conduct R&D discovery. Its two proprietary cancer molecules have already successfully passed the discovery stage and pre-clinical testing.

For one of its molecules, the company is challenging the traditional antiangiogenic approach to cancer therapy. Its neo-adjuvant therapy is designed to improve the efficacy of all types of chemo- and radiotherapy for solid tumors.

The company has also acquired a patent for an antitumor cationic amphipathic peptide (CAP6). It belongs to a new generation of cancer drugs with limited side effects and generally greater efficacy.

Proceeding to the next stages, the startup has completed the seed round raising of CHF 1 million from undisclosed investors. This bridging funding precedes a planned Series A round in late 2019, by which time important IP and clinical information will have become available.

(RAN)